<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654767</url>
  </required_header>
  <id_info>
    <org_study_id>LBILVR-KLI 884-B</org_study_id>
    <nct_id>NCT04654767</nct_id>
  </id_info>
  <brief_title>Inflammatory Profiling in Chronic Lung Disease</brief_title>
  <official_title>Inflammatory Profiling in Chronic Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Boltzmann Institute for Lung Vascular Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Boltzmann Institute for Lung Vascular Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the underlying inflammatory profile in patients with&#xD;
      chronic lung disease and determine the association pulmonary hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lung diseases (CLD), such as chronic obstructive pulmonary disease (COPD) and&#xD;
      idiopathic pulmonary fibrosis (IPF) are often complicated by the presence of pulmonary&#xD;
      hypertension (PH), where even a mild elevation of blood pressure in the pulmonary arteries is&#xD;
      associated with an even poorer prognosis. In this study, we will investigate whether&#xD;
      similarities exist in the inflammatory profile that could potentially underlie all forms of&#xD;
      pulmonary hypertension. Inflammatory data will be generated using flow cytometry, expression&#xD;
      profiling and histological analysis and compared to the associated clinical data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of inflammatory cell profile</measure>
    <time_frame>within 36 months</time_frame>
    <description>The number of leukocytes (CD45+ cells) and derivatives (percentage lymphocytes, monocytes and neutrophils) will be measured by flow cytometry in explanted lung tissue and blood of patients with CLD-PH and controls.&#xD;
Values will be reported as %CD45+ and %total cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of pulmonary vascular disease</measure>
    <time_frame>within 36 months</time_frame>
    <description>Pulmonary vascular disease will be assessed by associated clinical data (mPAP (mmHg), PVR (WU))&#xD;
CLD without PH (mPAP &lt;21 mmHg, or mPAP 21-24 mmHg with pulmonary vascular resistance (PVR) &lt;3 Wood Units (WU)).&#xD;
CLD with PH (mPAP 21-24 mmHg with PVR ≥3 WU, or mPAP 25-34 mmHg) (CLD-PH).&#xD;
CLD with severe PH (mPAP ≥35 mmHg, or mPAP ≥25 mmHg with low cardiac index (&lt;2.0 L·min-1·m-2)) (CLD-severe PH).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>COPD-PH group</arm_group_label>
    <description>Patients with confirmed COPD and pulmonary hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPF-PH</arm_group_label>
    <description>Patients with confirmed pulmonary fibrosis and pulmonary hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Control group without diagnosed COPD, IPF, or pulmonary hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissue sampling</intervention_name>
    <description>Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.&#xD;
Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls.</description>
    <arm_group_label>COPD-PH group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>IPF-PH</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, explant lung tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing lung transplantation at the Medical University of Vienna&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing lung transplant with COPD or IPF, with associated PH&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients without written informed consent&#xD;
&#xD;
          -  Signs of any infection such as pneumonia, pulmonary tuberculosis or infections with&#xD;
             pleural effusions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh Marsh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig Boltzmann Institute for Lung Vascular Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leigh Marsh</last_name>
    <phone>+4331638572911</phone>
    <email>leigh.marsh@lvr.lbg.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Klepetko, Prof</last_name>
      <phone>0043140400</phone>
      <phone_ext>56440</phone_ext>
      <email>walter.klepetko@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Gschwandtner, Dr</last_name>
      <phone>0043140400</phone>
      <phone_ext>56440</phone_ext>
      <email>elisabeth.gschwandtner@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular Diseases</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

